» Articles » PMID: 11513142

Human Natural Killer Cell Receptors and Co-receptors

Overview
Journal Immunol Rev
Date 2001 Aug 22
PMID 11513142
Citations 93
Authors
Affiliations
Soon will be listed here.
Abstract

In the absence of sufficient signaling by their HLA class I-specific inhibitory receptors, human natural killer (NK) cells become activated and display potent cytotoxicity against cells that are either HLA class I negative or deficient. This indicates that the NK receptors responsible for the induction of cytotoxicity recognize ligands on target cells different from HLA class I molecules. On this basis, the process of NK-cell triggering can be considered as a mainly non-MHC-restricted mechanism. The recent identification of a group of NK-specific triggering surface molecules has allowed a first series of pioneering studies on the functional/molecular characteristics of such receptors. The first three members of a receptor family that has been termed natural cytotoxicity receptors (NCR) are represented by NKp46, NKp44 and NKp30. These receptors are strictly confined to NK cells, and their engagement induces a strong activation of NK-mediated cytolysis. A direct correlation exists between the surface density of NCR and the ability of NK cells to kill various target cells. Importantly, mAb-mediated blocking of these receptors has been shown to suppress cytotoxicity against most NK-susceptible target cells. However, the process of NK-cell triggering during target cell lysis may also depend on the concerted action of NCR and other triggering receptors, such as NKG2D, or surface molecules, including 2B4 and NKp80, that appear to function as co-receptors rather than as true receptors. Notably, a dysfunction of 2B4 has been associated with a severe form of immunodeficiency termed X-linked lymphoproliferative disease. Future studies will clarify whether also the altered expression and/or function of other NK-triggering molecules may represent a possible cause of immunological disorders.

Citing Articles

The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies.

Wang Q, Yu M, Zhang S Front Immunol. 2025; 15:1440830.

PMID: 39877377 PMC: 11772360. DOI: 10.3389/fimmu.2024.1440830.


Comparison of Natural Killer Cells Differentiated from Various Pluripotent Stem Cells.

Han J, Son H, Jung D, Kim K, Jin C, Hwang H Int J Mol Sci. 2024; 25(15).

PMID: 39125777 PMC: 11311719. DOI: 10.3390/ijms25158209.


A novel NKp80-based strategy for universal identification of normal, reactive and tumor/clonal natural killer-cells in blood.

Moran-Plata F, Munoz-Garcia N, Gonzalez-Gonzalez M, Pozo J, Carretero-Dominguez S, Mateos S Front Immunol. 2024; 15:1423689.

PMID: 39040115 PMC: 11260609. DOI: 10.3389/fimmu.2024.1423689.


The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation.

Hadjis A, McCurdy S Front Immunol. 2024; 15:1358668.

PMID: 38817602 PMC: 11137201. DOI: 10.3389/fimmu.2024.1358668.


"HLA-C: evolution, epigenetics, and pathological implications in the major histocompatibility complex".

Velastegui E, Vera E, Vanden Berghe W, Munoz M, Orellana-Manzano A Front Genet. 2023; 14:1206034.

PMID: 37465164 PMC: 10350511. DOI: 10.3389/fgene.2023.1206034.